Evidence map›Paper›PMID 32320740›Full record

ArticleMetabolism: clinical and experimental2020

Letter to the Editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019.

Junli Fan, Hui Wang, Guangming Ye, Xiaoling Cao, Xianqun Xu, Wenbin Tan, Yongxi Zhang

Open access · bronzeAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Metabolism: clinical and experimental, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 9 pooled it
3.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 9 syntheses or guidelines pooled it, 177 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Article
  11. Article
  12. Article
  13. Review
  14. Observational
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Junli FanDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Hui WangDepartment of Laboratory Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Guangming YeDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Xiaoling CaoDepartment of Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, SC, USA.
Xianqun XuDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Wenbin TanDepartment of Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, SC, USA; Department of Biomedical Engineering, College of Engineering and Computing, University of South Carolina, Columbia, SC, USA. Electronic address: wenbin.tan@uscmed.sc.edu.
Yongxi ZhangDepartment of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China. Electronic address: znact1936@126.com.
Zhongnan Hospital of Wuhan University · CNUniversity of South Carolina · USUnion Hospital · CNWuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe pandemic of coronavirus disease 2019 (COVID-19) has become a global threat to public health. The lipid pathophysiology in COVID-19 is unknown.

methodsIn this retrospective longitudinal study, we monitored the serum lipids in 17 surviving and 4 non-surviving COVID-19 cases prior to their viral infections and duration the entire disease courses.

resultsIn surviving cases, the low-density lipoprotein (LDL) levels decreased significantly on admission as compared with the levels before infection; the LDL levels remained constantly low during the disease progression and resumed to the original levels when patients recovered (pre-infection: 3.5 (3.0-4.4); on admission: 2.8 (2.3-3.1), p < 0.01; progression: 2.5 (2.3-3.0); discharge: 3.6 (2.7-4.1); median (IQR), in mmol/L). In non-surviving patients, LDL levels showed an irreversible and continuous decrease until death (1.1 (0.9-1.2), p = 0.02 versus the levels on admission). The ratio changes of LDL levels inversely correlated with ratio changes of high-sensitivity C-reactive protein levels. Logistic regression analysis showed increasing odds of lowered LDL levels associated with disease progression (odds ratio: 4.48, 95% IC: 1.55-12.92, p = 0.006) and in-hospital death (odds ratio: 21.72, 95% IC: 1.40-337.54, p = 0.028).

conclusionsLDL levels inversely correlated to disease severities, which could be a predictor for disease progress and poor prognosis.

Indexed as

AgedBetacoronavirusChinaCholesterol, LDLComorbidityCoronavirus InfectionsCOVID-19C-Reactive ProteinDisease ProgressionFemaleHumansLongitudinal StudiesMaleMiddle AgedPandemicsPneumonia, ViralCholesterol, LDLC-Reactive ProteinCOVID-19LDLLipidOdds ratio

Identifiers

PMID32320740
PMCPMC7166305
OpenAlexW3016493664

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.